Biotechnology
%202.JPG/r%5Bwidth%5D=1280&r%5Bheight%5D=720/f8f1c0c0-b00a-11f0-9979-9313e8aa9ba8-Panel%203%20-%20AI-generated%20inventions%20(Kirkland%20%26%20Ellis%20Sponsored)%202.webp)
23 October 2025 A panel of experts at LSPN shared how AI is forcing companies to rethink everything from obviousness arguments to the choice between patents and trade secrets, and why the claims filed today may be invalid tomorrow.
23 October 2025
23 October 2025
22 October 2025
22 October 2025
9 October 2025
7 October 2025
Latest Features
Europe
As Big Pharma stalls investment in the UK, the government urgently needs to return to the negotiating table to salvage a key growth area, writes Tim Belcher of EIP.
Americas
In the second of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax delve into the real reasons why medicine costs more in the US.
Americas
In the first of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax explore how legislative, judicial, and executive policies have dramatically altered the risks for drug innovation.
Biotechnology
Erik Viik of Papula-Nevinpat looks at the dynamics that international applicants need to be aware of to secure and manage their patent rights across the region.
Americas
With growing legislation, research and demand for medical use, cannabis presents an economic opportunity for the Caribbean—but IP rights in the region have some way to go, write Keesha Fleming Lake of Keesha Fleming Lake, and Rachael Lodge Corrie of Foga Daley.
Americas
A patent fee structure being mooted in the US could hurt the innovation economy, especially in industries like biotech and pharma—and will face backlash from businesses, writes Paul Hunter of Foley.
Africa
Africa’s agricultural future is imperative to life and prosperity in the region—and the Arusha Protocol gives breeders the protection they need, explains the African Regional Intellectual Property Organization.
Europe
For those willing to undertake the complexity, in vivo cell therapy could redefine the economics and logistics of cell-based treatment, says Adam Gregory of Mewburn Ellis.
More News
2 October 2025 From stalled drug approvals to suspended patent investigations, US rightsholders face mounting uncertainty during the federal freeze.
1 October 2025 Research reveals an increase in global filings in 2024/2025, but concerns remain over the future of vaccine development in the US.
1 October 2025 The healthtech giant has convinced a US court to freeze the assets of two Chinese startups and their ex-employees for breaching an injunction for trade secret theft of X-ray tubes used in CT scanners.
29 September 2025 Complaint alleges the pair used Massachusetts company’s patented mRNA TALEN gene-editing technology without permission in multi-billion-dollar cancer therapy deals.
25 September 2025 The General Court has handed a win to generic drug makers including Teva and Mylan in the battle over multiple sclerosis drug Tecfidera.
24 September 2025 A biotech firm specialising in mRNA therapies alleges AbbVie’s $2.1 billion Capstan purchase was built on stolen lipid nanoparticle trade secrets.
23 September 2025 As John Squires is confirmed as the US Patent and Trademark Office's new director, Sarah Speight gathers reaction, and asks: what would you ask the US’ chief IP executive?
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox